Comparison of the efficacy and safety of using 0.01% versus 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind, split-face, comparative study.
Administration, Topical
Adult
Bimatoprost
/ administration & dosage
Dose-Response Relationship, Drug
Double-Blind Method
Eyebrows
/ diagnostic imaging
Female
Humans
Hypotrichosis
/ diagnosis
Male
Middle Aged
Ophthalmic Solutions
/ administration & dosage
Patient Satisfaction
Photography
Prospective Studies
Treatment Outcome
bimatoprost
comparison
efficacy
eyebrow
hypotrichosis
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
13
03
2019
accepted:
19
06
2019
pubmed:
19
7
2019
medline:
15
12
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Previous studies have proven the efficacy and safety of 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis; however, there is no comparison study between both concentrations. To compare the efficacy and safety between 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis. This prospective, randomized, double-blind, split-face clinical study was conducted in 30 patients with eyebrow hypotrichosis. Each side of eyebrow of individual patients was randomly assigned for 0.01% and 0.03% bimatoprost, applied on each eyebrow once daily. Eyebrow density, diameter, the Global Eyebrow Assessment scale, 7-point rating scale, and patient satisfaction were evaluated. Side effects were also recorded. Both 0.01% and 0.03% bimatoprost significantly improved eyebrow density and diameter (P < .05), although there were no statistically significant differences in changes in eyebrow density and diameter from baseline between both concentrations (P = .96 and .84, respectively). Additionally, patients significantly preferred 0.03% bimatoprost in terms of clinical improvement and satisfaction (P = .04 and .003, respectively). Both 0.01% and 0.03% bimatoprost are effective and safe for the treatment of eyebrow hypotrichosis. Bimatoprost 0.03% is superior to its 0.01% counterpart, albeit without statistical significance.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have proven the efficacy and safety of 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis; however, there is no comparison study between both concentrations.
AIMS
OBJECTIVE
To compare the efficacy and safety between 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis.
PATIENTS/METHODS
METHODS
This prospective, randomized, double-blind, split-face clinical study was conducted in 30 patients with eyebrow hypotrichosis. Each side of eyebrow of individual patients was randomly assigned for 0.01% and 0.03% bimatoprost, applied on each eyebrow once daily. Eyebrow density, diameter, the Global Eyebrow Assessment scale, 7-point rating scale, and patient satisfaction were evaluated. Side effects were also recorded.
RESULTS
RESULTS
Both 0.01% and 0.03% bimatoprost significantly improved eyebrow density and diameter (P < .05), although there were no statistically significant differences in changes in eyebrow density and diameter from baseline between both concentrations (P = .96 and .84, respectively). Additionally, patients significantly preferred 0.03% bimatoprost in terms of clinical improvement and satisfaction (P = .04 and .003, respectively).
CONCLUSIONS
CONCLUSIONS
Both 0.01% and 0.03% bimatoprost are effective and safe for the treatment of eyebrow hypotrichosis. Bimatoprost 0.03% is superior to its 0.01% counterpart, albeit without statistical significance.
Substances chimiques
Ophthalmic Solutions
0
Bimatoprost
QXS94885MZ
Types de publication
Equivalence Trial
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
714-719Subventions
Organisme : The Dermatological Society of Thailand
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365-372.
Klimko PG, Sharif NA. Discovery, characterization, and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol. 2018;176(8):1051-1058.
Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010;36(9):1361-1371.
Elias MJ, Weiss J, Weiss E. Bimatoprost ophthalmic solution 0.03% for eyebrow growth. Dermatol Surg. 2011;37(7):1057-1059.
Schweiger ES, Pinchover L, Bernstein RM. Topical bimatoprost for the treatment of eyebrow hypotrichosis. J Drugs Dermatol. 2012;11(1):106-108.
Riahi RR, Cohen PR. Topical treatment of eyebrow hypotrichosis with bimatoprost 0.03% solution: case report and literature review. Cureus. 2018;10(5):e2666.
Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% vs minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol. 2012;39(10):865-866.
Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. 2013;39(7):1079-1087.
Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J. 2014;20(6):13030/qt1mc5v5mx.
Carruthers J, Beer K, Carruthers A, et al. Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis. Dermatol Surg. 2016;42(5):608-617.
Suchonwanit P, Chanasumon N, Sriphojanart T. Efficacy and safety of bimatoprost 0.01% for the treatment of eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled study. Dermatol Surg. 2019. https://doi.org/10.1097/DSS.0000000000001944.
Nguyen JV. The biology, structure, and function of eyebrow hair. J Drugs Dermatol. 2014;13(1 Suppl):s12-s16.
Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14:323-328.
Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82:7-12.
Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):661.e1-671.e1.
Figus M, Nardi M, Piaggi P, et al. Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye (Lond). 2014;28(4):422-429.
Nokhodchi A, Shokri J, Dashbolaghi A, Hassan-Zadeh D, Ghafourian T, Barzegar-Jalali M. The enhancement effect of surfactants on the penetration of lorazepam through rat skin. Int J Pharm. 2003;250(2):359-369.
Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007;30(12):2360-2364.
Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg. 2010;36:638-649.
Isaac J, Scheinman PL. Benzalkonium chloride: an irritant and sensitizer. Dermatitis. 2017;28(6):346-352.